Trending Stock: Vascular Biogenics Ltd. (NASDAQ: VBLT)

VBL Therapeutics (VBLT) recently reported financial results for the third quarter ended September 30, 2019, and supplied a business update.

On 24 Jan 2020, Vascular Biogenics Ltd. stock recognized change of 59.14% away from 52-week low rate and just recently located move of -22.11% off 52-week high cost. VBLT stock has actually been taped 18.85% far from 50 day moving average and 16.98% far from 200 day moving average. Moving closer, we can see that shares have been trading 13.55% off 20-day moving average.

Third Quarter ended September 30, 2019 Financial Results:

Comprehensive Loss: VBL specified a net loss for the quarter ended September 30, 2019 of $4.9 M, or ($0.14) per share, contrast to a bottom line of $5.4 M, or ($0.15) per share, in the quarter ended September 30, 2018.

Earnings: Revenues related to VBLs partnerships were $0.1 M in the third quarter of 2019.

The typical volatility for the week at 4.26% and for month was at 5.60%. There are 35.39 M shares exceptional and 26.22 M shares are floated in market.

G&A Expenses: General and administrative expenditures for the quarter ended September 30, 2019 were $1.2 M, contrast to about $1.4 M in the same period in 2018.

Money Position: At September 30, 2019, the Company had cash, money equivalents, short-term bank deposits and limited bank deposits totaling $41.1 M and working capital of $34.5 M. The Company anticipates that its money, cash equivalents and short-term bank deposits will allow it to fund business expenses and capital expenditure requirements for about 2 years.

R&D Expenses: Research and advancement costs, internet, after government grants, were about $3.8 M for the quarter ended September 30, 2019, contrast to about $4.1 M in the same period in 2018.

Clarence Franklin

Clarence Franklin – Healthcare I am Clarence Franklin and I focus on breaking news stories and ensuring we (“TOP MAGAZINE WIRE”) offer timely reporting on some of the most recent stories released through market wires about “Healthcare” sector companies. I have formerly spent over 7 years as a trader in U.S. Stock Market and is now semi-stepped down.